Servier's Protelos and Osseor are still important despite VTE and skin concerns, says EMA
This article was originally published in Scrip
Executive Summary
Servier's bone drugs, Protelos and Osseor (strontium ranelate) is still an "important treatment" for women with osteoporosis, says the European Medicines Agency. The drugs' benefit: risk profile remains favourable, but the medicine is no longer to be recommended for certain patients, while warnings on serious skin reaction are to be updated.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.